T-C Wu Selected Research

herpes simplex virus type 1 protein VP22

7/2004	Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
3/2002	Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T-C Wu Research Topics

Disease

153	Neoplasms (Cancer) 05/2022 - 03/2002
32	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021 - 08/2003
23	Papillomavirus Infections 01/2021 - 01/2003
15	Ovarian Neoplasms (Ovarian Cancer) 04/2014 - 09/2005
14	Infections 01/2021 - 01/2003
9	Vaccinia 01/2021 - 11/2002
7	Carcinoma (Carcinomatosis) 01/2022 - 01/2003
6	Communicable Diseases (Infectious Diseases) 01/2022 - 10/2003
6	Carcinogenesis 12/2013 - 03/2006
5	Inflammation (Inflammations) 09/2016 - 05/2006
5	Virus Diseases (Viral Diseases) 03/2010 - 08/2003
4	Lung Neoplasms (Lung Cancer) 01/2017 - 05/2015
3	Squamous Cell Carcinoma of Head and Neck 04/2022 - 01/2003
3	Uterine Cervical Dysplasia 01/2021 - 02/2016
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 02/2007
3	Melanoma (Melanoma, Malignant) 01/2021 - 02/2012
3	Condylomata Acuminata (Genital Wart) 01/2021 - 10/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 09/2015 - 02/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2006
2	Hyperthermia 09/2015 - 01/2013
2	Adenocarcinoma 09/2015 - 08/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2015 - 08/2014
2	Necrosis 03/2010 - 11/2006
1	Hyperplasia 05/2022
1	COVID-19 12/2020
1	Choriocarcinoma 01/2019
1	Female Genital Neoplasms 01/2019
1	Tuberculosis (Tuberculoses) 11/2016

Drug/Important Bio-Agent (IBA)

67	AntigensIBA 01/2022 - 03/2002
56	VaccinesIBA 01/2022 - 01/2003
51	DNA VaccinesIBA 01/2021 - 03/2002
45	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2002
34	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
23	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2021 - 01/2003
20	Therapeutic UsesIBA 01/2018 - 04/2007
19	Peptides (Polypeptides)IBA 01/2022 - 09/2004
15	CalreticulinIBA 01/2017 - 08/2004
14	A-Form DNA (A-DNA)IBA 01/2021 - 05/2004
13	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 05/2008
11	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 11/2002
9	EpitopesIBA 01/2022 - 08/2005
9	Oncogene Proteins (Oncogene Protein)IBA 04/2021 - 02/2006
8	LuciferasesIBA 05/2019 - 06/2007
6	Capsid Proteins (Capsid Protein)IBA 01/2021 - 01/2003
6	MesothelinIBA 03/2013 - 02/2006
5	Neutralizing AntibodiesIBA 01/2015 - 01/2003
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 04/2022 - 01/2006
4	Bortezomib (Velcade)FDA Link 05/2014 - 08/2008
4	Small Interfering RNA (siRNA)IBA 01/2010 - 01/2005
3	Imiquimod (Aldara)FDA LinkGeneric 01/2021 - 04/2010
3	Interleukin-2 (IL2)IBA 01/2021 - 01/2012
3	CytokinesIBA 09/2016 - 07/2011
3	Cancer VaccinesIBA 09/2015 - 12/2003
3	Paclitaxel (Taxol)FDA LinkGeneric 07/2014 - 01/2013
3	Pharmaceutical PreparationsIBA 04/2014 - 01/2007
3	LigandsIBA 12/2013 - 08/2011
3	Histocompatibility Antigens Class IIBA 10/2013 - 08/2003
3	Proteasome InhibitorsIBA 05/2013 - 08/2008
3	Poly I-CIBA 08/2011 - 07/2004
3	AntibodiesIBA 08/2008 - 08/2003
3	Viral AntigensIBA 01/2007 - 08/2003
2	Immune Checkpoint InhibitorsIBA 04/2021 - 01/2021
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2021 - 08/2014
2	InterleukinsIBA 01/2021 - 01/2013
2	Vaccine AdjuvantsIBA 01/2018 - 09/2015
2	AgarIBA 03/2015 - 01/2012
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2014 - 09/2012
2	Tumor Viral Antigens (Large T Antigen)IBA 07/2013 - 02/2012
2	Death Domain ReceptorsIBA 05/2013 - 08/2008
2	Immunoglobulin G (IgG)IBA 02/2013 - 01/2005
2	Galactosylceramides (Galactocerebrosides)IBA 01/2013 - 10/2010
2	AllergensIBA 12/2012 - 11/2008
2	EnzymesIBA 01/2012 - 01/2005
2	Nucleic AcidsIBA 08/2011 - 04/2010
2	vadimezanIBA 07/2011 - 03/2011
2	Human papillomavirus type 16 oncogene protein E7IBA 07/2011 - 04/2007
2	RNA (Ribonucleic Acid)IBA 01/2010 - 07/2004
2	Amino Acids FDA Link 12/2008 - 06/2007
2	Monoclonal AntibodiesIBA 08/2008 - 02/2006
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 10/2007 - 08/2003
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 07/2007 - 02/2007
2	herpes simplex virus type 1 protein VP22IBA 07/2004 - 03/2002
1	Phenobarbital (Luminal)FDA Link 05/2022
1	Interferon Type IIBA 01/2022
1	Endoplasmic Reticulum Chaperone BiPIBA 05/2019
1	bromopyruvateIBA 05/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	IntegrinsIBA 01/2018
1	TransposasesIBA 01/2018
1	Isoniazid (Ftivazide)FDA LinkGeneric 11/2016
1	Guanosine Triphosphate (GTP)IBA 11/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2016

Therapy/Procedure

51	Immunotherapy 01/2022 - 03/2002
29	Therapeutics 01/2021 - 12/2003
15	Drug Therapy (Chemotherapy) 05/2015 - 02/2006
7	Radiotherapy 10/2014 - 03/2006
7	Investigational Therapies (Experimental Therapy) 07/2013 - 10/2007
4	Intraperitoneal Injections 05/2019 - 01/2007
2	Lasers (Laser) 09/2015 - 04/2009
1	Combined Modality Therapy 05/2019